Short Interest in Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) Decreases By 48.4%

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) was the target of a significant decline in short interest in June. As of June 30th, there was short interest totaling 37,772 shares, a decline of 48.4% from the June 15th total of 73,164 shares. Based on an average daily volume of 299,767 shares, the short-interest ratio is presently 0.1 days. Approximately 2.2% of the shares of the company are sold short.

Lakewood-Amedex Biotherapeutics Stock Performance

Shares of Lakewood-Amedex Biotherapeutics stock traded down $0.58 during trading on Thursday, reaching $1.85. The company’s stock had a trading volume of 187,820 shares, compared to its average volume of 307,450. The stock has a 50-day moving average price of $7.75. The company has a market capitalization of $3.24 million and a price-to-earnings ratio of -0.93. Lakewood-Amedex Biotherapeutics has a fifty-two week low of $1.76 and a fifty-two week high of $98.20.

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) last released its quarterly earnings results on Friday, May 22nd. The company reported ($2.00) EPS for the quarter.

Wall Street Analyst Weigh In

Separately, Wall Street Zen cut Lakewood-Amedex Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th.

Lakewood-Amedex Biotherapeutics Company Profile

We are a biotechnology company focused on leveraging unique, pioneering science to address unmet needs in the treatment of infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains, including methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococci species (VRE), and others. Antimicrobial resistance (AMR) represents a growing global health crisis, being directly responsible for 1.27 million deaths annually and contributing to nearly 5 million deaths worldwide.